Randomised study for double-blind, placebo-controlled evaluation of BI 765845 on top of standard of care in patients with myocardial infarction

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502788-39-00

Acronym

1478-0002

Enrollment

194

Registered

2023-10-30

Start date

2023-11-27

Completion date

2025-11-11

Last updated

2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Brief summary

Infarct severity

Interventions

DRUGPlacebo matching BI 765845

DRUGBI 765845

DRUGGadovist 1.0 mmol/ml solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Infarct severity	—

Countries

Czechia, Germany, Hungary, Italy, Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026